Parmax Pharma turns to a preferential issue after a 57% revenue crash.
A nano-cap with a ₹14 crore market cap, ₹4.16 crore in annual losses, and auditors flagging the Managing Director's fund use is seeking fresh equity.
— 1 earlier story on Parmax Pharma Ltd. →What's new
- Parmax Pharma's board will meet June 8 to evaluate a preferential issue of shares.
- Auditors flagged the Managing Director's unauthorized use of company funds.
- Annual revenue fell 57% and net losses widened to ₹4.16 crore.
Why this matters
This isn't a growth raise. It's a nano-cap with a collapsing business and an auditor flagging its MD. A preferential issue here is likely a survival move or a path to a control change, executed from a position of deep weakness.
What we're watching
- The identity and price of the preferential issue subscribers.
- Whether the auditor's governance findings lead to regulatory action.
- The terms of the shareholder EGM sought for approval.
The full read
Parmax Pharma's board meets on June 8 to weigh a preferential issue. The backdrop is grim. Revenue fell 57% last year. The net loss widened to ₹4.16 crore. The company's entire market cap is ₹14 crore. Worse, auditors have questioned how the Managing Director used company funds. For a nano-cap, this is not a routine capital raise. It's a lifeline, or a prelude to a control change. The price of the new shares and who buys them will define the outcome. The company is seeking shareholder approval, but the core signal is simple: Parmax needs money it doesn't have. The raise is a necessity, executed under a cloud of audit findings.
Questions answered
- Why is Parmax Pharma raising capital now?
- The company is in severe financial distress. Revenue slumped 57% in the last year, losses widened to ₹4.16 crore, and its entire market cap is just ₹14 crore. Auditors have also raised governance concerns about its Managing Director.
- What did auditors say about the Managing Director?
- The auditors reported the unauthorized use of company funds by the Managing Director. This governance failure compounds the company's operational and financial problems, making the need for new capital and oversight more acute.
- What does this fundraise mean for existing shareholders?
- A preferential issue sells new shares directly to a select group, which will dilute existing stakes. For a company this small and distressed, it often signals either a new strategic investor taking control or a desperate infusion of cash to stay afloat.
- Are insiders restricted from trading?
- Yes. Trading in Parmax securities is suspended for designated persons until June 10. This follows the material announcement of a potential fundraise to prevent informed trading.
Story so far
All notes on PARMAX →- 3 Jun 2026 · 9:18 PM IST Parmax Pharma turns to a preferential issue after a 57% revenue crash.
- today Parmax Pharma revenue halved, auditors flag MD's use of company funds